Induction of immunity against antigens expressed on tumor cells might prevent or delay recurrence of the disease. Six patients operated on for colorectal carcinoma were immunized with human monoclonal anti-idiotypic anti-
Monoclonal antibodies (mAbs) directed against tumorassociated antigens (TAAs) have been used in cancer therapy. Treatment with native mAbs might inhibit growth and induce regression of tumors in man (1, 2) . According to the idiotypic network theory (3), the infused mAb (the idiotope antibody, Ab1) might elicit humoral and cellular anti-idiotypic and anti-anti-idiotypic responses. Such indirect effector mechanisms induced by the mAb have been proposed to be of therapeutic benefit (4) (5) (6) . In Ab1-treated patients, parts of the variable regions of the induced anti-idiotypic antibodies (Ab2) might resemble the epitope that Ab1 recognizes-i.e., the nominal antigen. In various systems, Ab2 mimicking epitopes of an antigen have successfully been used for immunization as a surrogate for the antigen (7) .
The mouse mAb 17-1A recognizes the TAA GA733-2 (also referred to as C017-1A), which is expressed in most human colorectal tumors (8) . Inoculation of this mAb had anti-tumor effects in colorectal carcinoma (CRC) patients (1, 9) . In the present study, we have used human monoclonal Ab2 (h-Ab2) against mAb 17-lA (Ab1) (10) for immunization of patients operated on for CRC. These h-Ab2 induced an Ab1-like humoral immune response in mice (11) . Here we describe the humoral and cellular immune responses evoked in CRC patients by immunization with these h-Ab2.
MATERIALS AND METHODS
Patients. Six patients with a mean age of 57 years (range, 40-67 years) who had been operated on for Dukes' class B (n The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
= 2) or C (n = 4) CRC with no remaining tumor entered the study. No other systemic anti-tumor therapy was given between primary surgery and the start of immunization (2-20 months) or during the immunization period. Informed consent was obtained from all patients.
Production of h-Ab2. The production and specificity tests of our h-Ab2 have been described (6, 10 A control protein preparation (RPMI/FBS control) was purified by applying the same purification procedures to complete medium as described for h-Ab2-containing culture supernatants.
Immunization Protocol. Patients 1, 2, 5, and 6 were immunized with 0.5 mg of h-Ab2 at weeks 0, 2, 4, 6, 8, and 14. Patients 3 and 4 were given 0.5 mg of h-Ab2 at week 0 and then 1.0 mg of h-Ab2 at weeks 2, 4, 6, and 14. In patients 5 and 6 h-Ab2 were given unconjugated, whereas in patients 1-4 h-Ab2 were given conjugated with immunogenic peptides of the Bordetella pertussis toxin subunit S1 (h-Ab2/peptide weight ratio, 4:1) (12), except at week 14 in patients 3 and 4. Patient 1 had an additional dose of unconjugated h-Ab2 at week 26. All injections were given subcutaneously with the immunogen precipitated in alum (National Bacteriological Laboratory, Stockholm).
Production of the Antigen GA733-2E. The TAA GA733-2 is defined by mAb 17-1A and mAb GA733 (8, 13) . The extracellular domain of the antigen (GA733-2E) was produced in the baculovirus expression system as described (13) except that serum-free medium (SF 900II; GIBCO) was used during the whole culture period and detergent was omitted from the elution buffer for immunoaffinity chromatography. The baculovirus-produced antigen gpl60 and a baculovirus control protein were used as in vitro controls (14) ITo whom reprint requests should be addressed.
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Medical Sciences: Fagerberg et at scribed (15) . M058 is a human mAb [IgGl(K)] with specificity for a cytomegalovirus-related protein (16) . M058 was produced and purified in the same way as h-Ab2.
Production of Peptides. Twenty-three (P1-P23) 18 -aa peptides (with 6-aa N-and C-terminal overlap in each peptide) derived from the entire amino acid sequence of GA733-2E (13) were synthesized by 9-fluorenylmethoxycarbonyl methodology (17) .
ELISA. Antibodies against antigens were assayed in ELISA essentially as described (6) . The antigens and the coating concentration were as follows: GA733-2E-derived peptides (5 ,g/ml); GA733-2E, gpl60, baculovirus control protein, mAb GA733, mAb 17-1A, and mAb 425 (2.5 ,zg/ml); and tetanus toxoid (1 ,ug/ml Competition RIA. Antibodies binding to SW1116, a human CRC cell line expressing the antigen GA733-2, were determined as described (6) . In brief, tumor cells were incubated with undiluted serum, washed, and then incubated with 125I-labeled mAb 17-1A. The results are expressed as percent inhibition of 125I-labeled mAb 17-1A binding to tumor cells.
Undiluted serum from 25 healthy controls induced an inhibition of 3.8 ± 0.8% (mean ± SEM; mean + 2 SD = 12.1%). Inhibition of :15% by a serum was considered to indicate the presence of antibodies binding to the tumor cells (6) .
Mixed Hemadsorption Assay (MHA). Antibodies recognizing SW1116 cells were determined by MHA as described (6) . The results are expressed as percent of tumor cells forming rosettes with indicator cells binding human IgG. Healthy donors gave 6.0 ± 0.5% rosettes (mean ± SEM, n = 35). Serum was scored as positive when >15% rosettes were found.
Proliferation Assay (DNA Synthesis). Peripheral blood mononuclear cells (PBMCs), T cells, adherent cells, and monocytes were isolated as described (6) . Tests were done on (i) fresh PBMCs or (ii) T cells supplemented with 5% monocytes or adherent cells. In some experiments, frozen PBMCs were thawed and used either alone or mixed with 5% fresh autologous monocytes or adherent cells. The cells were cultured for 6 days and incubated with [methyl-3H]thymidine for the last 18 hr (6) . Antigen concentration were 0.1 pg/ml to 10 ,ug/ml for h-Ab2, h-IgG1, M058, RPMI/FBS control, mAb 17-1A, mAb BR55-2 and 0.1 pg/ml to 0.1 ,ug/ml for GA733-2E, gpl60, and the baculovirus control protein. Delayed-Type Hypersensitivity (DTH). h-Ab2 (0.1 mg) was injected intradermally. As a control, human pooled polyclonal IgG (,y-globulin; Pharmacia) (0.1 mg) was used. Induration and erythema were measured 24-48 hr after the injection (18 Anti-TAA and Anti-Ab2 Humoral Response. Five of the six patients immunized with h-Ab2 developed IgG antibodies which bound to the TAA GA733-2E (Table 1 ). The kinetics of induction of antibodies are shown in Fig. 1 . Maximum antibody titers, defined as the highest dilution giving an absorbance value > mean + 2 SD, of healthy controls and the preimmunization sera varied between 1:50 and 1:400 (data not shown). Preimmune sera and sera with the highest anti-GA733-2E titer of each patient were checked for binding to various mouse mAbs (GA733, 425, and 17-1A), the baculovirus-produced gp160, and the baculovirus control protein. In none of the patients was a significant difference between pre-and postimmunization sera detected (data not shown). No significant change in the IgG titers against tetanus toxoid was noted during or after immunization (data not shown). Pre-and postimmunization sera were extensively checked for IgM antibodies against GA733-2E but no such antibodies were detected (data not shown).
Antibodies against human CRC cells expressing GA733-2 were also detected by a competition RIA and MHA (Table 2) . Sera which were positive in these assays also had antibodies against baculovirus-produced GA733-2E (Table 1) .
Overlapping peptides (n = 23) derived from the entire extracellular domain of the TAA, GA733-2E, were used to map B-cell epitopes. All five patients with antibodies against the complete GA733-2E molecule and tumor cell bound GA733-2 also showed binding to practically only one (P3) of the 23 peptides (Fig. 2) . Antibodies of the patients' preimmunization sera or sera of healthy controls did not bind to any of the 23 peptides (data not shown). Sera of the five patients containing antibodies against GA733-2E and P3 also reacted with h-Ab2. Preincubation of individual patient sera with h-Ab2 (10 ,ug/ml) inhibited the binding to GA733-2E between 33% and 82% and to P3 between 39% and 84%. Preincubation with polyclonal human IgG (10 ,ug/ml) inhibited the binding to GA733-2E by 0-8% and to P3 by 0-6% (data not shown).
Cellular Response Against GA733-2E and h-Ab2: DNA Synthesis. In an in vitro proliferation assay all patients showed a specific T-cell response against h-Ab2 (Table 3 ). The T-cell response against h-Ab2 was also analyzed in cell samples which were frozen at various times during the observation period and then thawed and assayed at one time point. The results were essentially the same as for fresh cells (Table 4) . A specific cellular response against GA733-2E was also induced in all patients ( Table 5) .
As controls, patient lymphocytes were checked for a proliferative response against mAb M058, RPMI/FBS control protein, mouse mAbs 17-1A and BR55-2, baculovirusproduced gpl60, and the baculovirus control protein. None of these control antigens induced a significant T-cell response (stimulation index < 2.75) (data not shown).
Cellular Response Against h-Ab2: Production of IFN-y and IL-2. In all tested patients, h-Ab2-specific T cells secreting IFN-,y or IL-2 were noted ( Table 6 ). The simultaneous rise in h-Ab2-specific cells secreting IFN-,y and IL-2 is exemplified in Fig. 3 .
h-Ab2-Reactive T Cells in Vivo (DTH). Five of the six patients developed a DTH reaction after challenge with h-Ab2 ( Table  7) . None of these patients had a DTH response to h-Ab2 when challenged before immunization. DISCUSSION h-Ab2 against mAb 17-1A (Ab1) were used for immunization of six patients operated on for CRC. These h-Ab2 have previously been shown to mimic the TAA GA733-2 defined by mAb 17-1A (10, 11) .
Five of the six patients developed antibodies that bound to the baculovirus-produced GA733-2E and to tumor cells expressing the antigen. By using overlapping peptides derived from GA733-2E, a putative B-cell epitope localized to an 18-aa peptide close to the N terminus of the TAA was found. The anti-TAA and anti-peptide (P3) IgG antibodies of the immu- nized patients also recognized epitope(s) within the variable regions of h-Ab2.
In all patients a specific proliferative T-cell response was induced against the CRC TAA GA733-2E and h-Ab2. The cell-mediated response was of considerable duration (>2 years). Lymphocytes from all patients were specifically stimulated by h-Ab2 to secrete IFN--y or IL-2. h-Ab2-specific DTH reaction was also noted. In this limited material the humoral and cellular immune responses did not seem to depend on the dose of h-Ab2 in the range we used or on whether h-Ab2 were conjugated to pertussis peptides or not.
Many Ab2 which mimic TAA and microbial antigens have been produced for immunization as a surrogate for the nominal antigen. Most of them were of animal origin, but also a few human Ab2 have been produced (10, (19) (20) (21) . Immunization with Ab2 in TAA systems induced anti-tumor effects without side effects in patients with malignant diseases (19, 20, 22) . The ability to induce an anti-tumor immunity varied among Ab2. For some Ab2, only a humoral response was reported (19, 20) . Other Ab2 did not induce antibodies but only a T-cell response against the nominal antigen (21, 23). However, Ab2 like ours appear to induce both a cellular and a humoral immune response.
In a hepatitis B system, it was shown that a murine Ab2 expressed epitopes that mimicked a peptide of the hepatitis B surface antigen for both B and T cells. The Ab2 appeared to activate T cells through the same mechanisms as used by the nominal antigen. Moreover, the Ab2 elicited a cellular and humoral response in an outbred strain of mice and also in a strain not responsive to the nominal antigen (24) . Thus, an Ab2 vaccine that contains specific epitopes that can stimulate T and 
